The poster discusses innovative strategies to efficiently screen large compound libraries in drug discovery programmes. ​ Affinity Selection Mass Spectrometry (ASMS), a high-throughput screening technology, is known for its sensitivity and specificity in analysing target-ligand interactions. ​The poster highlights the importance of strategic pool compression, ranging from 5 to over 3000 compounds per pool, using redundancy-minimising algorithms to avoid mass ambiguity in hit identification and contingent critical determinants in selecting the optimal route in the designed workflow. The prioritisation of these factors necessitates a strategic compromise between cost-effectiveness and turnaround time, depending on the overarching objectives of the workflow.

The poster emphasises BioAscent's robust, automated tube-based selection and picking system in 96 and 384 well formats, which accelerates turnaround times and supports the high throughput needs of AI drug discovery.